title: p53 analysis in gallbladder cancer: comparison of gene analysis versus immunohistochemistry.
abstract: BACKGROUND
  The survival of gallbladder cancer (GC) patients is generally poor. Both after resection and palliative procedures, additive therapy is often administered to increase outcome. The effect of cytotoxic therapies depends on a functioning p53 gene. The aim of this study was to investigate whether p53 immunohistochemistry (IHC) or p53 gene sequencing are of any survival influence in GC.
  
  
  METHODS
  In 61 GC patients, 19 were resected and in 42 operative explorations were performed. Seven resected and 14 palliated patients received adjuvant chemotherapy. IHC p53 staining and DNA sequencing was investigated.
  
  
  RESULTS
  p53 sequencing detected 20 mutations and no relationship was found between IHC and sequencing results. After resection chemotherapy increased survival in those having a normal p53 gene compared to those having a mutation (p=0.008). p53 status did not show an influence in resected patients without chemotherapy or in palliative-treated patients regardless of their therapy.
  
  
  CONCLUSIONS
  p53 protein overexpression does not correlate with p53 gene mutation. Response to chemotherapy in resected GC patients may depend on a functioning p53 gene.
authors.affiliation: Department of General Surgery, University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
authors.forename: H
authors.initials: H
authors.lastname: Puhalla
authors.forename: D
authors.initials: D
authors.lastname: Kandioler
authors.forename: C
authors.initials: C
authors.lastname: Ludwig
authors.forename: M
authors.initials: M
authors.lastname: Filipits
authors.forename: F
authors.initials: F
authors.lastname: Wrba
authors.forename: F
authors.initials: F
authors.lastname: Laengle
authors.forename: R
authors.initials: R
authors.lastname: Jakesz
authors.forename: T
authors.initials: T
authors.lastname: Gruenberger
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism; D017024:Chemotherapy, Adjuvant; D004273:DNA, Neoplasm / Q000235:genetics; D005260:Female; D005706:Gallbladder Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000378:metabolism* / Q000601:surgery; D016158:Genes, p53 / Q000235:genetics*; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D009154:Mutation; D012680:Sensitivity and Specificity; D017422:Sequence Analysis, DNA; D016896:Treatment Outcome; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism*
chemical_list: D014408:Biomarkers, Tumor; D004273:DNA, Neoplasm; D016159:Tumor Suppressor Protein p53